An Integrative Bioinformatics Platform with Application in Single Cancer Cells
应用于单个癌细胞的综合生物信息学平台
基本信息
- 批准号:9321082
- 负责人:
- 金额:$ 34.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-09-01 至 2020-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acute Erythroblastic LeukemiaAcute Myelocytic LeukemiaAddressBig DataBioinformaticsBiologicalBiological AssayCancer cell lineCell LineCellsCollaborationsCommunitiesComputer softwareComputing MethodologiesCopy Number PolymorphismDataData SetDevelopmentEvolutionGeneric DrugsGenesGeneticGenetic PolymorphismGenomicsGoalsHematologistHeterogeneityHumanIndividualK-562K562 CellsLaboratoriesMalignant NeoplasmsMessenger RNAMethodologyMethodsMethylationModelingMyeloid LeukemiaNoiseNucleotidesPathway interactionsPatientsPatternPlayPopulationQuality ControlResearch PersonnelResolutionRoleSample SizeSamplingServicesSourceStem cellsTechnologyTestingTissuesTreatment EfficacyUniversitiesValidationVariantbasecancer cellcarbenedata integrationdesignexomeexome sequencingexperimental studygenome-widegenomic variationimprovedinsertion/deletion mutationinsightleukemiamethylomeneoplastic cellnew technologynovelrestriction enzymesingle cell analysissingle cell sequencingsuccesstherapeutic targettooltranscriptometranscriptome sequencingtumortumor heterogeneityuser-friendly
项目摘要
Project Summary
Human cancers are highly heterogeneous. However, due to the limit of technologies, the intercellular
heterogeneity was not detectable genome-wide at single-cell level until recently. New technologies such as
single-cell RNA-Seq and exome-Seq have revealed new insights and more profound complexity than what was
previously thought. In collaboration with Dr. Weissman's group in the Genetics Department at Yale University,
it is now feasible to perform multiple integrative assays from the same single tumor cell. However, rigorous
computational methods are still lagging behind, in order to solve the computational challenge and determine
true heterogeneity rather than noise. Here we propose a user-friendly bioinformatics platform that is optimized
to integrative multiple types of single-cell NGS data, in particular, transcriptome, exome and CpG methylome
data that are all obtained from the same cell. Specifically, in this study we will first construct and validate in
parallel three new NGS bioinformatics pipelines to enable single-cell based RNA-Seq, exome- Seq, and CpG
methylome data. We will then develop and validate an integration pipeline to analyze multiple types of high-
throughput data, exemplified by the RNA-Seq, exome-Seq and CpG methylome single-cell data. To test the
software suite, we will first obtain data sets from erythroleukemia cell line K562. We will then utilize this
bioinformatics suite to investigate heterogeneity in Myeloid Leukemia patient samples provided by
hematologist Dr. Stephanie Halene at Yale Stem Cell Center. Beyond deciphering tumor heterogeneity, this
user-friendly bioinformatics platform is expected to be used widely by the single-cell sequencing community.
项目摘要
人类癌症是高度异质性的。然而,由于技术的限制,
直到最近才在单细胞水平上检测到全基因组异质性。等新技术
单细胞RNA-Seq和exome-Seq揭示了新的见解和更深刻的复杂性,
以前认为。在与耶鲁大学遗传学系Weissman博士的团队合作下,
现在可以从同一单个肿瘤细胞进行多个综合测定。然而,严格
计算方法仍然落后,为了解决计算挑战并确定
真正的异质性,而不是噪音。在这里,我们提出了一个用户友好的生物信息学平台,
整合多种类型的单细胞NGS数据,特别是转录组、外显子组和CpG甲基化组
这些数据都是从同一个细胞中获得的。具体来说,在这项研究中,我们将首先构建和验证
并行三个新的NGS生物信息学管道,以实现基于单细胞的RNA-Seq,外显子组- Seq和CpG
甲基化数据。然后,我们将开发和验证集成管道,以分析多种类型的高-
通过RNA-Seq、外显子组-Seq和CpG甲基化组单细胞数据例示的通量数据。测试
软件套件,我们将首先从红白血病细胞系K562获得数据集。我们将利用这个
研究髓性白血病患者样本异质性的生物信息学套件,由
耶鲁干细胞中心的血液学家斯蒂芬妮·哈琳博士说。除了破译肿瘤异质性,
用户友好的生物信息学平台有望被单细胞测序界广泛使用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Lana X Garmire其他文献
Lana X Garmire的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Lana X Garmire', 18)}}的其他基金
DR. EPS: Drug Repurposing for Extended Patient Survival
博士。
- 批准号:
10022322 - 财政年份:2019
- 资助金额:
$ 34.45万 - 项目类别:
DR. EPS: Drug Repurposing for Extended Patient Survival
博士。
- 批准号:
10186808 - 财政年份:2019
- 资助金额:
$ 34.45万 - 项目类别:
DR. EPS: Drug Repurposing for Extended Patient Survival
博士。
- 批准号:
10465034 - 财政年份:2019
- 资助金额:
$ 34.45万 - 项目类别:
An Integrative Bioinformatics Platform with Application in Single Cancer Cells
应用于单个癌细胞的综合生物信息学平台
- 批准号:
10004166 - 财政年份:2016
- 资助金额:
$ 34.45万 - 项目类别:
Cancer precision medicine through spatially informative single cell image and transcriptomics data analysis
通过空间信息单细胞图像和转录组学数据分析进行癌症精准医学
- 批准号:
10754028 - 财政年份:2016
- 资助金额:
$ 34.45万 - 项目类别:
An Integrative Bioinformatics Platform with Application in Single Cancer Cells
应用于单个癌细胞的综合生物信息学平台
- 批准号:
9160242 - 财政年份:2016
- 资助金额:
$ 34.45万 - 项目类别:
An Integrative Omics Approach to Identify Biomarkers Related to Preeclampsia and Breast Cancer Risks
识别与先兆子痫和乳腺癌风险相关的生物标志物的综合组学方法
- 批准号:
9162127 - 财政年份:2016
- 资助金额:
$ 34.45万 - 项目类别:
An Integrative Omics Approach to Identify Biomarkers Related to Preeclampsia and Breast Cancer Risks
识别与先兆子痫和乳腺癌风险相关的生物标志物的综合组学方法
- 批准号:
9542867 - 财政年份:2016
- 资助金额:
$ 34.45万 - 项目类别:
An Integrative Omics Approach to Identify Biomarkers Related to Preeclampsia and Breast Cancer Risks
识别与先兆子痫和乳腺癌风险相关的生物标志物的综合组学方法
- 批准号:
10076552 - 财政年份:2016
- 资助金额:
$ 34.45万 - 项目类别:
An Integrative Bioinformatics Approach to Study Single Cancer Cell Heterogeneity
研究单个癌细胞异质性的综合生物信息学方法
- 批准号:
9095313 - 财政年份:2014
- 资助金额:
$ 34.45万 - 项目类别:
相似海外基金
Computing analysis of leukemic stem cell dynamics in acute myelocytic leukemia
急性粒细胞白血病白血病干细胞动力学的计算分析
- 批准号:
19K08356 - 财政年份:2019
- 资助金额:
$ 34.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Generation of immunotoxins with super-targeting mAb in the acute myelocytic leukemia
在急性髓细胞白血病中使用超靶向单克隆抗体产生免疫毒素
- 批准号:
23501309 - 财政年份:2011
- 资助金额:
$ 34.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556971 - 财政年份:1980
- 资助金额:
$ 34.45万 - 项目类别:
DETERMINANTS OF RESPONSE OF ACUTE MYELOCYTIC LEUKEMIA
急性粒细胞白血病反应的决定因素
- 批准号:
3556968 - 财政年份:1980
- 资助金额:
$ 34.45万 - 项目类别:
ERADICATION OF ACUTE MYELOCYTIC LEUKEMIA CELLS BY MAB THERAPY
通过 MAB 疗法根除急性粒细胞白血病细胞
- 批准号:
3889304 - 财政年份:
- 资助金额:
$ 34.45万 - 项目类别:














{{item.name}}会员




